New long term biotech research cooperation deal signed by Brazil and UK

18 June 2013

The British Biotechnology and Biological Sciences Research Council (BBSRC) and the Brazilian National Council for Scientific and Technological Development (CNPq) have signed a Letter of Understanding to implement a new cooperation program to extend the long-term collaboration between the parties. Steve Visscher, deputy chief executive, signed for the BBSRC while CNPq was represented by its president, Glaucius Oliva.

Activities under the cooperation program will include launching calls for research partnership proposals, providing funding for the proposals selected, organising joint workshops related to common projects and other forms of scientific and technological cooperation. The signed Letter will add new impetus to a long-standing collaboration between scientists from both countries. The UK-Brazil Year of Science & Innovation in 2007, the joint Brazil-UK Agrosciences workshop in 2008 and the establishment of an Embrapa Laboratory Exterior (LabEx) in the UK are just a few important milestones of this relationship.

Commenting, Glaucius Oliva said: “CNPq and BBSRC already have a fruitful cooperation over the years. We want a program and a scheme which are much more efficient and accessible for researchers in both countries and this is what the signing was all about today (…) It will open a tremendous door for Brazilian scientists to interact with UK scientists.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology